Company Description
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy.
It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease.
In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines.
It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi.
The company was incorporated in 1989 and is headquartered in Carlsbad, California.
| Country | United States |
| Founded | 1989 |
| IPO Date | May 17, 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,069 |
| CEO | Brett Monia |
Contact Details
Address: 2855 Gazelle Court Carlsbad, California 92010 United States | |
| Phone | 760 931 9200 |
| Website | ionis.com |
Stock Details
| Ticker Symbol | IONS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000874015 |
| CUSIP Number | 462222100 |
| ISIN Number | US4622221004 |
| Employer ID | 33-0336973 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brett P. Monia Ph.D. | Founder, Chief Executive Officer and Director |
| Elizabeth L. Hougen M.A., M.B.A., M.S. | Executive Vice President of Finance and Chief Financial Officer |
| Patrick R. O'Neil Esq. | Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary |
| Dr. Richard S. Geary Ph.D. | Executive Vice President and Chief Development Officer |
| Kyle Jenne | Executive Vice President and Chief Global Product Strategy Officer |
| Darren Gonzales | Chief Accounting Officer and Senior Vice President |
| Dr. C. Frank Bennett BSc, Ph.D. | Executive Vice President and Chief Scientific Officer |
| D. Wade Walke Ph.D. | Senior Vice President of Investor Relations |
| Tracy Berns J.D. | Senior Vice President and Chief Compliance and Quality Assurance Officer |
| Hayley Soffer | Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 30, 2025 | 144 | Filing |
| Jul 30, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 30, 2025 | 10-Q | Quarterly Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 10, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| Apr 30, 2025 | 10-Q | Quarterly Report |
| Apr 30, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |